GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
|
|
- Brittney May
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: GSK A, GSK A, GSK A, GSK A, GSK A, GSK A Study Number: (RSV F-001) Title: An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals Respiratory Syncytial Virus (RSV) investigational vaccine (GSK A) in healthy men. GSK A (RSV): GlaxoSmithKline (GSK) Biologicals RSV investigational vaccine. Rationale: The purpose of this first-time-in-humans study was to evaluate the safety and immunogenicity of 6 investigational RSV vaccine formulations, when administered as a single intramuscular dose to healthy men aged 18 to 44 years. 3 different concentrations of the active compound were evaluated: low-dose (LD), medium-dose (MD) and -high-dose (HD); each one administered either non-adjuvanted or adjuvanted with aluminium. A placebo was used as control. The subjects were followed-up for approximately 1 year after vaccination, starting from Day 0 up to, and including, Day 360. This summary presents results up to the Day 60 time point (primary completion date). When the results collected beyond the Day 60 time point are available, this summary will be updated. GSK A (RSV-LD): GSK Biologicals RSV vaccine, in a LD formulation, non-adjuvanted. GSK A (RSV-LD alum): GSK Biologicals RSV vaccine, LD formulation, aluminium-adjuvanted. GSK A (RSV-MD): GSK Biologicals RSV vaccine, MD formulation, non-adjuvanted. GSK A (RSV-MD alum): GSK Biologicals RSV vaccine, MD formulation, aluminium-adjuvanted. GSK A (RSV-HD): GSK Biologicals RSV vaccine, HD formulation, non-adjuvanted. GSK A (RSV-HD alum): GSK Biologicals RSV vaccine, HD formulation, aluminium-adjuvanted. Phase: I Study Period: 22 July 2013 to 9 April 2014 (Day 60 time point,) Study Design: Randomized, observer-blind, single-country, placebo-controlled, dose-escalation* study with 2 steps and 8 groups; 5 in Step 1 (randomization ratio 1:1:1:1:1) and 3 in Step 2 (randomization ratio 1:1:1) *Refer to the Treatment Section below for details on dose-escalation procedures in this study. Centres: 3 centers in Canada Indication: Administration of RSV investigational vaccine in healthy men aged 18 to 44 years Treatment: Study groups were as follows: RSV-LD (Step 1): Subjects received one dose of non-adjuvanted RSV-LD vaccine. RSV-LD alum (Step 1): Subjects received one dose of aluminium-adjuvanted RSV-LD vaccine. RSV-MD (Step 1): Subjects received one dose of non-adjuvanted RSV-MD vaccine. RSV-MD alum (Step 1): Subjects received one dose of aluminium-adjuvanted RSV-MD vaccine. RSV-HD (Step 2): Subjects received one dose of non-adjuvanted RSV-HD vaccine. RSV-HD alum (Step 2): Subjects received one dose of aluminium-adjuvanted RSV-HD vaccine. Control-1 (Step 1): Subjects received one dose of placebo solution. Conrol-2 (Step 2): Subjects received one dose of placebo solution. The RSV vaccine and placebo solution were administered intramuscularly in the deltoid. Enrolment in this study was conducted in a staggered manner, including 2 steps. During Step 1, the LD and MD formulations of the RSV vaccine, non-adjuvanted or adjuvanted with alum, were evaluated. Thereafter, during Step 2, the HD formulations of the RSV vaccine, non-adjuvanted or adjuvanted with alum, were evaluated. Enrolment for this Step 2 was conditional on the favorable outcome of the evaluation of safety data collected from subjects enrolled in Step 1, up to 7 days after vaccination. The safety evaluation was performed by an Internal Safety Review Committee Objectives: To evaluate the safety and tolerability of a single intramuscular dose of the RSV investigational vaccines, up to 60 days after vaccination. Primary Outcome Variable: Occurrence of adverse events (AEs) from vaccination to Day 60, in all subjects, in all groups: o Occurrence of each solicited local and general AE, during a 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days). o Occurrence of any hematological (hemoglobin level, white blood cell [WBC], lymphocyte, neutrophil, eosinophil
2 and platelet count) and biochemical (alanine amino-transferase [ALT], aspartate amino-transferase [AST] and creatinine) laboratory abnormality at Day 0, Day 7, Day 30 and Day 60. Occurrence of any unsolicited AE, during a 30-day follow-up period after vaccination (i.e. the day of vaccination and 29 subsequent days). Occurrence of any Serious Adverse Events (SAEs) from Day 0 to Day 60. Secondary Outcome Variable(s): Humoral immune response to the investigational RSV vaccines, pre-vaccination (Day 0) and post-vaccination (Day 7, Day 30 and Day 60), in all subjects, in all groups: Neutralizing antibody titers against RSV subgroup A. Neutralizing antibody titers against RSV subgroup B. Enzyme-linked Immunosorbent Assay (ELISA) antibody titers against RSV. Occurrence of AEs, in all subjects, in all groups*: Occurrence of any hematological (hemoglobin level, WBC, lymphocyte, neutrophil, eosinophil and platelet count) and biochemical (ALT, AST and creatinine) laboratory abnormality at Day 180 and Day 360. Occurrence of any SAE from Day 60 to the study conclusion. Persistence of the humoral immune response to the investigational RSV vaccines, at Day 180 and Day 360, in all subjects, in all groups*: Neutralizing antibody titers against RSV subgroup A. Neutralizing antibody titers against RSV subgroup B. ELISA antibody titers against RSV. * This summary presents results up to the Day 60 time point. When the results collected beyond the Day 60 time point are available, this summary will be updated. Statistical Methods: The analysis was performed on the Total Vaccinated cohort and on the According-to-Protocol (ATP) cohort for immunogenicity: - The Total Vaccinated cohort included all subjects with study vaccine administration documented. - The ATP cohort for immunogenicity included all subjects, included in the Total Vaccinated cohort meeting all eligibility criteria and for whom the administration route and site of the vaccine was according the protocol, who did not have received a vaccine not specified or forbidden in the protocol up to Day 30 visit and who, up to the Day 60 visit, did not receive a concomitant medication/ product or present with a medical condition leading to exclusion from the ATP analysis and who complied with the protocol-specified timing of the 30 days and 60 days post-vaccination blood sample and for whom post-vaccination immunogenicity results were available for at least 1 anti-rsv assay for at least one time point. Analysis of Safety The analysis was performed on Total Vaccinated cohort. The percentage of subjects with solicited local and general symptoms during the 7-day follow-up period after vaccination was tabulated for each group with exact 95% confidence interval (CI). The same tabulation was performed for Grade 3 solicited local and general symptoms and for solicited general symptoms assessed by the investigator as related to the study vaccination. For each group and for each hematology and biochemistry parameter, the percentage of subjects having hematology and biochemistry results below or above the local laboratory normal ranges with reference to baseline was tabulated by time point. The percentage of subjects reporting the occurrence of unsolicited AE during the 30-day follow-up period after vaccination was classified by Medical Dictionary for Regulatory Activities (MedDRA) preferred term and tabulated by group. The percentages of subjects with SAEs as well as the number of subjects with SAEs assessed by the investigator as related to study vaccination, from study start up to Day 60 were to be classified by MedDRA preferred term and tabulated by group. Analysis of Immunogenicity The analysis was performed on the ATP cohort for immunogenicity. For the anti-rsv humoral immune response, for each group, at each time point that blood samples were collected for the anti- RSV-A and anti-rsv-b neutralization assay (cut-off = 8 and 6 ED60 respectively) and for the anti-rsv ELISA assay (cut-off = 5 EU/mL), the following was performed: -The percentage of subjects above the cut-off and their exact 95% CI was tabulated. -Geometric mean concentrations/titers (GMCs/GMTs) and their 95% CI were calculated. Study Population: Healthy males between, and including, 18 and 44 years of age at the time of vaccination were enrolled in the study. Subjects were excluded from the study if they had had previous vaccination against RSV, any confirmed or suspected immunosuppressive or immunodeficient condition, a family history of congenital or hereditary immunodeficiency, history of or current autoimmune disease, history of any reaction or hypersensitivity likely to be exacerbated by any
3 component of the vaccines, any clinically significant hematological (hemoglobin level, WBC, lymphocyte, neutrophil, eosinophil and platelet count) and biochemical (ALT, AST and creatinine) abnormality, as per the opinion of the investigator based on the local laboratory normal ranges. Subjects with a minor illness (such as mild diarrhea) without fever could be enrolled at the discretion of the investigator. Written informed consent was obtained from subjects prior to any stud procedure. Number of Subjects: RSV-LD RSV-LD RSV-MD RSV-MD RSV-HD RSV-HD Control Control alum alum alum 1 2 Planned, N Randomized, N (Total Vaccinated cohort) Completed to Day 60, n (%) 16 (100) 15 (93.8) 15 (100) 15 (93.8) 16 (100) 16 (100) 17 (100) 16 (100) Number of subjects withdrawn, N (%) 0 (0.0) 1 (6.2) 0 (0.0) 1 (6.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Withdrawn due to Adverse Events n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Withdrawn due to Lack of Efficacy n (%) Not applicable Withdrawn for other reasons n (%) 0 (0.0) 1 (6.2) 0 (0.0) 1 (6.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Demographics RSV-LD RSV-LD RSV-MD RSV-MD RSV-HD RSV-HD Control Control alum alum alum 1 2 N (Total Vaccinated cohort) Males, n (%) 16 (100) 16 (100) 15 (100) 16 (100) 16 (100) 16 (100) 17 (100) 16 (100) Mean Age, years (SD) 32.1 (7.80) 32.1 (7.39) 33.7 (6.56) 32.3 (7.22) 31.1 (7.92) 32.8 (6.18) 29.3 (8.04) 30.8 (7.55) Median Minimum, Maximum 20, 43 20, 41 21, 43 22, 44 20, 43 21, 42 18, 43 20, 44 White - Caucasian / European Heritage, n (%) 11(68.8) 11 (68.8) 13 (86.7) 10 (62.5) 6 (37.5) 7 (43.8) 12 (70.6) 8 (50.0) Asian - South East Asian Heritage, n (%) 3 (18.8) 1 (6.3) 2 (13.3) 2 (12.5) 5 (31.3) 8 (50.0) 2 (11.8) 6 (37.5) African Heritage / African American, n (%) 1 (6.3) 2 (12.5) 0 (0.0) 2 (12.5) 4 (25.0) 1 (6.3) 0 (0.0) 1 (6.3) Primary Outcome Results: Incidence of solicited local symptoms reported during the 7-day (Days 0-6) post-vaccination period (Total Vaccinated cohort) RSV-LD RSV-LD alum RSV-MD RSV-MD alum 95 % CI 95 % CI 95 % CI 95 % CI Symptom Intensity N n % LL UL N n % LL UL N n % LL UL N n % LL UL Pain Any Grade Redness Any >100 mm Swelling Any >100 mm RSV-HD RSV-HD alum Control 1 Control 2 95 % CI 95 % CI 95 % CI 95 % CI Symptom Intensity N n % LL UL N n % LL UL N n % LL UL N n % LL UL Pain Any Grade Redness Any >100 mm Swelling Any >100 mm N = number of subjects with the documented dose n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit Any = incidence of a particular symptom regardless of grade. Grade 3 pain = significant pain at rest. Symptom which prevented normal everyday activities
4 Primary Outcome Results: Incidence of solicited general symptoms reported during the 7-day (Days 0-6) post-vaccination period (Total Vaccinated cohort) RSV-LD RSV-LD alum RSV-MD RSV-MD alum 95 % CI 95 % CI 95 % CI 95 % CI Symptom Intensity /Relatio nship N n % LL UL N n % LL UL N n % LL UL N n % LL UL Fatigue Any Grade Related Gastrointestinal symptoms Any Grade Related Headache Any Grade Related Temperature (Oral) Symptom 37.5 C >39.5 C Related RSV-HD RSV-HD alum Control 1 Control 2 95 % CI 95 % CI 95 % CI 95 % CI Intensity Relation ship N n % LL UL N n % LL UL N n % LL UL N n % LL UL Fatigue Any Grade Related Gastrointestina l symptoms Any Grade Related Headache Any Grade Related Temperature (Oral) 37.5 C >39.5 C Related N = number of subjects with the documented dose n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit Any = incidence of a particular symptom regardless of grade or relationship to vaccination Grade 3 = symptom which prevented normal everyday activities Related = symptom assessed by the investigator(s) to be causally related to study vaccination. Primary Outcome Results: Distribution of change from baseline in hematology and biochemistry parameters up to Day 60 with respect to normal laboratory ranges (Total Vaccinated cohort) RSV-LD RSV-LD alum Unknown Below Within Above Unknown Below Within Above N n % n % n % n % N n % n % n % n % Laboratory parameter Baseline Timing (PRE) ALT PI(D7) Unknown Within Above Within Above
5 Within Above AST PI(D7) Unknown Within Above Within Above Within Above Creatinine PI(D7) Unknown Below Within Above Below Within Above Below Within Above Eosinophils PI(D7) Unknown Within Above PI(D30) Unknown Within Above PI(D60) Unknown Within Above Hemoglobin PI(D7) Unknown Within Above PI(D30) Unknown Within Above PI(D60) Unknown Within Above WBC PI(D7) Unknown Within
6 PI(D30) Unknown Within PI(D60) Unknown Within Lymphocytes PI(D7) Unknown Below Within PI(D30) Unknown Below Within PI(D60) Unknown Below Within Neutrophils PI(D7) Unknown Below Within PI(D30) Unknown Below Within PI(D60) Unknown Below Within Platelets PI(D7) Unknown Below Within PI(D30) Unknown Below Within PI(D60) Unknown Below Within RSV-MD RSV-MD alum Unknown Below Within Above Unknown Below Within Above Laboratory parameter Baseline Timing (PRE) N n % n % n % n % N n % n % n % n % ALT PI(D7) Unknown Within Above Within Above
7 Within Above AST PI(D7) Unknown Within Above Within Above Within Above Creatinine PI(D7) Unknown Within Above Within Above Within Above Eosinophils PI(D7) Unknown Within Above Within Above Within Above Hemoglobin PI(D7) Unknown Within Above Within Above Within Above WBC PI(D7) Unknown Below Within
8 Below Within Below Within Lymphocytes PI(D7) Unknown Below Within Below Within Below Within Neutrophils PI(D7) Unknown Below Within Below Within Below Within Platelets PI(D7) Unknown Below Within Below Within Below Within RSV-HD RSV-HD alum Unknown Below Within Above Unknown Below Within Above Laboratory parameter Baseline Timing (PRE) N n % n % n % n % N n % n % n % n % ALT PI(D7) Unknown Within Above Within Above
9 Within Above AST PI(D7) Unknown Within Above Within Above Within Above Creatinine PI(D7) Unknown Within Within Within Eosinophils PI(D7) Unknown Within Above Within Above Within Above Hemoglobin PI(D7) Unknown Below Within Above Below Within Above Below Within Above WBC PI(D7) Unknown Below Within
10 Below Within Below Within Lymphocytes PI(D7) Unknown Below Within Below Within Below Within Neutrophils PI(D7) Unknown Below Within Below Within Below Within Platelets PI(D7) Unknown Within Above Within Above Within Above Control 1 Control 2 Unknown Below Within Above Unknown Below Within Above Laboratory parameter Baseline Timing (PRE) N n % n % n % n % N n % n % n % n % ALT PI(D7) Unknown Within Above PI(D30) Unknown Within Above
11 PI(D60) Unknown Within Above AST PI(D7) Unknown Within Above PI(D30) Unknown Within Above PI(D60) Unknown Within Above Creatinine PI(D7) Unknown Below Within Above PI(D30) Unknown Below Within Above PI(D60) Unknown Below Within Above Eosinophils PI(D7) Unknown Within Above PI(D30) Unknown Within Above PI(D60) Unknown Within Above Hemoglobin PI(D7) Unknown Within Above PI(D30) Unknown Within Above PI(D60) Unknown Within Above WBC PI(D7) Unknown Below Within
12 PI(D30) Unknown Below Within PI(D60) Unknown Below Within Lymphocytes PI(D7) Unknown Below Within PI(D30) Unknown Below Within PI(D60) Unknown Below Within Neutrophils PI(D7) Unknown Below Within PI(D30) Unknown Below Within PI(D60) Unknown Below Within Platelets PI(D7) Unknown Below Within PI(D30) Unknown Below Within PI(D60) Unknown Below Within N = number of subjects with available results for the specified laboratory parameter and timing in a given baseline category n/% = number/percentage of subjects in the specified category Unknown = missing normal laboratory range for the specified laboratory parameter Below = below the normal laboratory range defined for the specified laboratory parameter Within = within the normal laboratory range defined for the specified laboratory parameter Above = above the normal laboratory range defined for the specified laboratory parameter PI(D7) = Post-vaccination at Day 7 PI(D30) = Post-vaccination at Day 30 PI(D60) = Post-vaccination at Day 60 Primary Outcome Results: For results about unsolicited AEs and SAEs, please refer to the safety section of the document. Secondary Outcome Results: Number and percentage of subjects with Anti-RSV-A neutralizing antibody titer equal to or above the seropositivity threshold and GMTs, up to Day 60 (ATP cohort for immunogenicity)
13 8 ED60 GMT 95% CI 95% CI Antibody Timing N n % LL UL value LL UL Anti-RSV A Neutralizing Antibody RSV-LD PRE PI(D7) PI(D30) PI(D60) RSV-LD alum PRE PI(D7) PI(D30) PI(D60) RSV-MD PRE PI(D7) PI(D30) PI(D60) RSV-MD alum PRE PI(D7) PI(D30) PI(D60) RSV-HD PRE PI(D7) PI(D30) PI(D60) RSV-HD alum PRE PI(D7) PI(D30) PI(D60) Control 1 PRE PI(D7) PI(D30) PI(D60) Control 2 PRE PI(D7) PI(D30) PI(D60) GMT = geometric mean antibody titer calculated on all subjects N = number of subjects with available results n/% = number/percentage of subjects with titer equal to or above specified value 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PRE = Pre-vaccination at Day 0 PI(D7) = Post-vaccination at Day 7 PI(D30) = Post-vaccination at Day 30 PI(D60) = Post-vaccination at Day 60 Secondary Outcome Results: Number and percentage of subjects with Anti-RSV-B neutralizing antibody titer equal to or above the seropositivity threshold and GMTs, up to Day 60 (ATP cohort for immunogenicity) 6 ED60 GMT 95% CI 95% CI Antibody Timing N n % LL UL value LL UL Anti-RSV B RSV-LD PRE Neutralizing PI(D7) Antibody PI(D30) RSV-LD alum PI(D60) PRE PI(D7) PI(D30)
14 PI(D60) RSV-MD PRE PI(D7) PI(D30) PI(D60) RSV-MD alum PRE PI(D7) PI(D30) PI(D60) RSV-HD PRE PI(D7) PI(D30) PI(D60) RSV-HD alum PRE PI(D7) PI(D30) PI(D60) Control 1 PRE PI(D7) PI(D30) PI(D60) Control 2 PRE PI(D7) PI(D30) PI(D60) GMT = geometric mean antibody titer calculated on all subjects N = number of subjects with available results n/% = number/percentage of subjects with titer equal to or above specified value 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PRE = Pre-vaccination at Day 0 PI(D7) = Post-vaccination at Day 7 PI(D30) = Post-vaccination at Day 30 PI(D60) = Post-vaccination at Day 60 Secondary Outcome Results: Number and percentage of subjects with ELISA Anti-RSV PreF antibody concentration equal to or above the seropositivity threshold and GMCs (ATP cohort for immunogenicity) 10 EU/mL GMC (EU/mL) 95% CI 95% CI Antibody Timing N n % LL UL value LL UL Anti-RSV RSV-LD PRE PreF PI(D7) antibody PI(D30) RSV-LD alum PI(D60) PRE PI(D7) PI(D30) PI(D60) RSV-MD PRE PI(D7) PI(D30) PI(D60) RSV-MD alum PRE PI(D7) PI(D30) PI(D60) RSV-HD PRE
15 RSV-HD alum Control 1 Control 2 PI(D7) PI(D30) PI(D60) PRE PI(D7) PI(D30) PI(D60) PRE PI(D7) PI(D30) PI(D60) PRE PI(D7) PI(D30) PI(D60) GMC = geometric mean antibody concentration calculated on all subjects N = number of subjects with available results n/% = number/percentage of subjects with concentration equal to or above specified value 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PRE = Pre-vaccination at Day 0 PI(D7) = Post-vaccination at Day 7 PI(D30) = Post-vaccination at Day 30 PI(D60) = Post-vaccination at Day 60 Safety Results: Percentage of subjects reporting the occurrence of unsolicited AEs within the 30-day (Days 0-29) postvaccination period (Total Vaccinated cohort) Most frequent adverse events - On-Therapy (occurring within Days 0-29 following vaccination) RSV-LD RSV-LD alum RSV-MD RSV-MD alum RSV-HD RSV-HD alum Control 1 Control 2 N = 15 N = 17 Subjects with any AE(s), n (%) 4 (25.0) 6 (37.5) 5 (33.3) 4 (25.0) 6 (37.5) 4 (25.0) 4 (23.5) 3 (18.8) Headache - 2 (12.5) (18.8) - 2 (11.8) - Cough 1 (6.3) 2 (12.5) (6.3) - - Injection site bruising 1 (6.3) (12.5) (6.3) Upper respiratory tract infection 1 (6.3) 1 (6.3) (11.8) - Nasopharyngitis (6.7) 1 (6.3) - 1 (6.3) - - Rhinorrhoea 1 (6.3) (5.9) 1 (6.3) Aspartate aminotransferase increased (6.3) (6.3) Diarrhoea 1 (6.3) 1 (6.3) Myalgia (6.7) 1 (6.3) Oropharyngeal pain (6.3) 1 (6.3) - - Sinus headache - 1 (6.3) 1 (6.7) Asthenia (6.3) Back pain (6.7) Constipation (5.9) - Dizziness (6.7) Feeling hot (6.3) Gastroenteritis (6.3) Gastroenteritis viral (6.3) Laceration - 1 (6.3) Lymphadenopathy (6.3) Nasal congestion - 1 (6.3) Nausea 1 (6.3) Pain in extremity - 1 (6.3) Pulmonary congestion - 1 (6.3) Pyrexia (6.3) - - Respiratory tract infection (6.7)
16 Rhinitis (6.7) Sinus congestion (5.9) - Sinusitis 1 (6.3) Throat irritation - 1 (6.3) Throat tightness (6.7) Viral infection (6.3) - - Safety Results: Number (%) of subjects with serious adverse events up to Day 60 (Total Vaccinated cohort) Serious Adverse Event, n (%) [n assessed by the investigator to be related to study medication] All SAEs Subjects with any SAE(s), n (%) [n assessed by the investigator as related] Fatal SAEs Subjects with any SAE(s), n (%) [n assessed by the investigator as related] RSV-LD RSV-LD alum RSV-MD N = 15 RSV-MD alum RSV-HD RSV-HD alum Control 1 N = 17 Control 2 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] RSV-LD RSV-LD alum RSV-MD N = 15 RSV-MD alum RSV-HD RSV-HD alum Control 1 N = 17 Control 2 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0)[0] 0 (0.0) [0] 0 (0.0)[0] Conclusion: During the 7-day (Days 0-6) post-vaccination period, pain at the injection site was the most frequently reported solicited local AE, reported by 12.5% (2 out of 16) of the subjects in the RSV-LD up to 81.3% (13 out of 16) of the subjects in the RSV-MD alum, as compared to 5.9% and 12.5% (1 and 2 subjects respectively) in CONTROL1 and CONTROL 2 groups respectively. Grade 3 pain was reported for 1 subject in the RSV-HD alum. During the 7-day (Days 0-6) post-vaccination period, fatigue and headache were the most frequently reported solicited general symptoms. Fatigue was reported for 18.8% of the subjects (3 out of 16) in the RSV-LD, RSV-MD alum and RSV-HD-alum s, up to 43.8% (7 out of 16) of the subjects in the RSV-LD alum and RSV-HD s, as compared to11.8% (2 subjects) and 25% ( 4 subjects) in CONTROL1 and CONTROL 2 s respectively. Grade 3 fatigue was reported for 1 subject in the RSV-LD (considered related to vaccination by the investigator) and by 2 subjects in the RSV-LD alum (considered non-related to vaccination by the investigator). Headache was reported by 12.5% (2 out of 16) of the subjects in the RSV-LD up to 43.8% (7 out of 16) of the subjects in the RSV-HD as compared to 11.8% (2 out of 17) and 37.5% (6 out of 16) in CONTROL1 and CONTROL 2 groups respectively.. Grade 3 headache was reported for 2 subjects in the RSV-LD alum (considered non-related to vaccination by the investigator). During the 30-day (Days 0-29) post-vaccination period, unsolicited AEs were reported for 4 (25%) subjects in the RSV-LD, RSV-MD alum and RSV-HD alum s, 5 (33.3%) subjects in the RSV-MD and 6 (37.5%) subjects in the RSV-LD alum and RSV-HD s as compared to 4 (23.5%) and 3 (18.8%) subjects in CONTROL1 and CONTROL 2 s respectively. No SAEs were reported up to Day 60. Date updated: 17-Nov-2014
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPanzyga Administration Guide
Immune Human Normal Globulin Immunoglobulin Intravenous (Human) (IVIg) Octapharma s new Intravenous Immunoglobulin (IVIG) Panzyga Administration Guide An educational service tool provided by Octapharma
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218
More informationpopulation Completed double-blind 458 (67.7) 445 (65.0) study n (%)
Study No: ARIA3002 Year 4 Title: A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression
More informationNew Directions in Aplastic Anemia: What is on the Horizon
Case Presentation #1 New Directions in Aplastic Anemia: What is on the Horizon Gabrielle Meyers, MD 62 y/o male, with hypertension, who presented to his PCP for evaluation of fatigue, shortness of breath
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationSOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS
University of Oklahoma Office of Human Research Participant Protection : PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS 1. POLICY Protocol deviations and unanticipated problems may be discovered in a variety
More informationStudy Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB)
Study Management SM 302.00 STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval:
More informationWHY IS PREVENTION IMPORTANT?
A GUIDE TO TRUST THE POWER OF PREVENTION < 2 > WHY IS PREVENTION IMPORTANT? Hereditary angioedema (HAE) symptoms can range in severity. Some attacks may be mild or temporarily disabling, but others can
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More informationSelf-declaration by New Zealand of its status of freedom from Equine Viral Arteritis
Self-declaration by New Zealand of its status of freedom from Equine Viral Arteritis Self-declaration submitted to the OIE on xxxx2014, by Dr Matthew Stone, Chief Veterinary Officer, Ministry for Primary
More information1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride
1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride
More informationSTAYING ON TRACK WITH CINRYZE THERAPY
YOUR GUIDE TO STAYING ON TRACK WITH CINRYZE THERAPY Indication CINRYZE (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks
More informationFINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM
750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationTREATMENT GUIDE. Your treatment. Your questions answered.
TREATMENT GUIDE Your treatment. Your questions answered. INDICATIONS: Kineret is a prescription medicine called an interleukin-1 receptor antagonist (IL-1ra) used to: Reduce the signs and symptoms, and
More informationThe Science of. NUTRICULA Longevity Journal
32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,
More informationAMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016 The Duke University Health System Institutional Review Board (DUHS IRB) requires that
More informationSafety Data Sheet European Format
Safety Data Sheet European Format Preparation Date 09-Jan-2007 Revision Date 09-Sep-2008 Revision Number 2 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Product Name Common
More informationSUPPLEMENTARY APPENDIX. Ary Serpa Neto MD MSc, Fabienne D Simonis MD, Carmen SV Barbas MD PhD, Michelle Biehl MD, Rogier M Determann MD PhD, Jonathan
1 LUNG PROTECTIVE VENTILATION WITH LOW TIDAL VOLUMES AND THE OCCURRENCE OF PULMONARY COMPLICATIONS IN PATIENTS WITHOUT ARDS: a systematic review and individual patient data metaanalysis SUPPLEMENTARY APPENDIX
More informationCounty of Santa Clara Emergency Medical Services System
County of Santa Clara Emergency Medical Services System Policy # 700-S01 Ebola Virus Prevention and Control EBOLA VIRUS PREVENTION AND CONTROL Effective: October 30, 2014 Replaces: October 8, 2014 (Version
More informationOXYGEN FOR ADULTS IN ACUTE CARE
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF OXYGEN FOR ADULTS IN ACUTE CARE ALL CLINICAL DIVISIONS ADULT CARE STATEMENT The staff indicated in Staff Group may administer oxygen in the two detailed
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationBiltmore Challenge 2011 Final Report Draft 1
Biltmore Challenge 2011 Final Report Draft 1 Michael I. Lindinger, PhD, Dept. of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, Canada N1G 2W1 Email: mlinding@uoguelph.ca The
More information21 C&HT. Concussion and Head Trauma Policy. Codes and Policies
21 Concussion and Head Trauma Policy Codes and Policies 20 21 CRICKET AUSTRALIA Concussion and Head Trauma Policy Version: 2.0 Date last reviewed: 1 September 2016 Review frequency: Annual The CRICKET
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Animal Health Pfizer Inc 235 East 42nd Street New York, NY 10017 Poison Control Center Phone: 1-866-531-8896
More informationHemoglobin g/dl Female Male 12 years and older 11.9 to to 17.5
Reference Ranges: updated 6-21-18 Parameter Age WBC x 0 to 3 days 9.0 to 30.0 3 days to 2 weeks 5.0 to 21.0 2 weeks to 1 month 5.0 to 20.0 1 month to 2 years 6.0 to 17.5 2 years to 6 years 5.0 to 15.5
More informationAnalysis of Variance. Copyright 2014 Pearson Education, Inc.
Analysis of Variance 12-1 Learning Outcomes Outcome 1. Understand the basic logic of analysis of variance. Outcome 2. Perform a hypothesis test for a single-factor design using analysis of variance manually
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic
More informationConfirmation of the Drug-drug Interaction Potential Between Cobicistat-boosted Antiretroviral Regimens and Hormonal Contraceptives
Confirmation of the Drug-drug Interaction Potential Between Cobicistat-boosted Antiretroviral Regimens and Hormonal Contraceptives Sophia R. Majeed, Steve K. West, Shuping Jiang, Jessica Andrews, Savita
More informationUnassisted breathing and death as competing events in critical care trials
Unassisted breathing and death as competing events in critical care trials William Checkley, MD, PhD Johns Hopkins University November 22, 2011 wcheckl1@jhmi.edu Objectives Jointly model the frequency
More informationSupplementary Online Content
Supplementary Online Content McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia: a Randomized Clinical Trial.
More informationPackage Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)
Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains
More informationFrank Zanzuccki, Executive Director. See Summary below for explanation of exception to calendar requirement
LAW AND PUBLIC SAFETY NEW JERSEY RACING COMMISSION Horse Racing Anti-Recombinant Human EPO Antibody Testing Program Proposed New Rule: Authorized By: N.J.A.C. 13:70-14A.12 New Jersey Racing Commission,
More informationSecond Quarter 2018 Results Call Corporate Update & Financial Results. August 7, 2018
Second Quarter 2018 Results Call Corporate Update & Financial Results August 7, 2018 Forward-Looking Statements BioCryst s presentation may contain forward-looking statements, including statements regarding
More informationIATA Guidance for airline health and safety staff on the medical response to Cabin Air Quality Events
IATA Guidance for airline health and safety staff on the medical response to Cabin Air Quality Events (Smoke, Fumes/odours) 1. Introduction Much controversy exists in relation to the potential health ramifications
More informationCinryze. Cinryze (C1 esterase inhibitor [human]) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.05 Subject: Cinryze Page: 1 of 5 Last Review Date: September 20, 2018 Cinryze Description Cinryze
More information3.1. Substances Not applicable 3.2. Mixtures Name Product identifier %
Date of issue: 04/06/2018 Revision date: 04/06/2018 Version: 1.0 SECTION 1: Identification 1.1. Identification Product form Product name : Mixture : 1.2. Recommended use and restrictions on use Recommended
More informationTREATMENT AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES
PLANNING FOR TREATMENT AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES ADVANCES IN HEP C TREATMENT LEARN MORE ABOUT HEP C There s never been a better time to treat Hep C. Recent scientific advances
More information: Accu-Sed Plus Normal & Abnormal ESR Control Kit
SECTION 1: Identification 1.1. Identification Product form Product name Product code : Mixture : Accu-Sed Plus Normal & Abnormal ESR Control Kit : DS-71002, DS-71003, DS-71004, DS-71005A, DS-71006 1.2.
More informationAcute Mountain Sickness
Innere Medizin VII / Sportmedizin Acute Mountain Sickness Peter Bärtsch www.klinikum.uni-heidelberg.de/sportmedizin AMS: Clinical Picture Symptoms: - Headache - Loss of appetite, nausea, vomiting - Dizziness
More informationName May 3, 2007 Math Probability and Statistics
Name May 3, 2007 Math 341 - Probability and Statistics Long Exam IV Instructions: Please include all relevant work to get full credit. Encircle your final answers. 1. An article in Professional Geographer
More informationProcedure Department: HUMAN RESEARCH PROTECTIONS PROGRAM Policy Number: II.B.1
Procedure Department: HUMAN RESEARCH PROTECTIONS PROGRAM Policy Number: II.B.1 Section: HRPP Compliance Review Responsibility: HRPP Policy and Procedure Committee Original Creation Dare: November 1, 2003
More informationPatient Information. Physician Information
Patient Information CONTINUE ONLY IF: Not currently prescribed or taking medications: Bleomycin, Disulfiram, Mafernide Acetate Do not have or suspect having: Hereditary Sperocytosis, Sickle Cell Anemia,
More informationSITE NAME: ISF DOCUMENT VERSION CHECKLIST Complete yes or no to confirm the presence or absence of each document specified.
1. TRIAL MANAGEMENT CTC Contact List 8 29/07/2016 Y N CTC Contact List (superseded) 7 29/09/2015 Y N CTC Contact List (superseded) 6 24/02/2015 Y N CTC Contact List (superseded) 5 03/09/2014 Y N CTC Contact
More informationHealthy Calves for 4-H Calf Club Projects and Ontario Calf Shows
Healthy Calves for 4-H Calf Club Projects and Ontario Calf Shows Information compiled by the Ontario Association of Bovine Practitioners Calf Health Team including: Dr s Tim Henshaw (Eastgen), Christie
More informationWRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Schistosomiasis WRAIR- GEIS 'Operational Clinical Infectious Disease' Course The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or
More informationName Product identifier % Classification (GHS-US)
SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product form Product name. Product code : Mixture : Synthetic Blood : SYNB8 1.2. Relevant identified
More informationSECOND EUROPEAN CONSENSUS CONFERENCE ON HYPERBARIC MEDICINE THE TREATMENT OF DECOMPRESSION ACCIDENTS IN RECREATIONAL DIVING
SECOND EUROPEAN CONSENSUS CONFERENCE ON HYPERBARIC MEDICINE THE TREATMENT OF DECOMPRESSION ACCIDENTS IN RECREATIONAL DIVING MARSEILLE, May 8-10, 1996 RECOMMENDATIONS OF THE JURY* QUESTION 1 : Is there
More informationAsk the Vet April Stephen D. Fisch, DVM
Ask the Vet April 2013 Stephen D. Fisch, DVM www.avsequinehospital.com 850-386-3619 Ask the Vet with Dr. Steve Fisch, DVM What is the recommended vaccination schedule for broodmares and foals and why?
More informationStandardized Adult ( kg) IVIG Infusion Rate Tables
Gammagard Liquid 10% For complete product information please refer to product monograph. Patient Weight in Kilograms Rate 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 ml/kg/hr Infusion
More informationStandardized Pediatric (20-70 kg) IVIG Infusion Rate Tables
Gammagard Liquid 10% For complete product information please refer to product monograph. Rate ml/kg/hr Patient Weight in Kilograms 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 55 60 65 70 Infusion Rate
More informationSafety Data Sheet. Document Group: Version Number: 2.00 Issue Date: 06/01/15 Supercedes Date: 10/03/12
3M Clean-Trace Water Plus - Total ATP 06/01/15 Safety Data Sheet Copyright,2015,3M Company. All rights reserved. Copying and/or downloading of this information for the purpose of properly utilizing 3M
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More information3.1. Substance Not applicable Mixture Name Product identifier % None by HazCom 2012 criteria
Date of issue: 09/09/2015 Revision date: 09/09/2015 Version: 1.0 SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code : :
More informationBBS Fall Conference, 16 September Use of modeling & simulation to support the design and analysis of a new dose and regimen finding study
BBS Fall Conference, 16 September 211 Use of modeling & simulation to support the design and analysis of a new dose and regimen finding study Didier Renard Background (1) Small molecule delivered by lung
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationRisk of spread after introduction of the virus in to wild boar population
Available tools for the prevention and control of diseases in wildlife, with focus on ASF in wild boar in infected country: hunting biosecurity and wild boar carcass disposal Marius Masiulis FAO international
More informationMaterial Safety Data Sheet (ATTAR-C)
Janes Industrial Products, LLC PO Box 81282 Lafayette, LA 70598 (337) 269-6306 Material Safety Data Sheet HMIS HEALTH:...1 HMIS FLAMMABILITY:...0 HMIS REACTIVITY:...0 PERSONAL PROTECTION:...B EMERGENCY
More informationEspilat Mountaineering Club
In the name of God Espilat Mountaineering Club May 2013 MEDICAL PROBLEMS IN HIGH MOUNTAIN ENVIRONMENTS Arya Hamedanchi MD, MPH Level one International Anthropometrist International Certificate of Ski Medicine
More informationSECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY
Revision Date: 02/19/2014 Version: 1.0 SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY 1.1. Product Identifier Product Form: Mixture Product Name: FLAMETEC TM CP7-D 1.2. Intended
More informationThe use of risk management as best practice to reduce outbreaks of recreational water illnesses in disinfected swimming facilities and spas
The use of risk management as best practice to reduce outbreaks of recreational water illnesses in disinfected swimming facilities and spas Roy Vore, Ph.D., NSPF I, CPO Vore & Associates, LLC Email: Roy.D.Vore@gmail.com
More information: KIDS N PETS NO NO NO! Carpet & Upholstery Protectant/Pet Deterrent
KIDS N PETS NO NO NO! Carpet & Upholstery Protectant/Pet Deterrent Date of issue: 07/04/2017 Revision date: 07/04/2017 Version: 1.0 SECTION 1: Identification 1.1. Identification Product form Product name
More informationZODIAQ Quartz Surfaces
This SDS adheres to the standards and regulatory requirements of the United States and may not meet the regulatory requirements in other countries. SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product
More informationLab 17. The Respiratory System. Laboratory Objectives
Lab 17 The Respiratory System Laboratory Objectives Identify and describe the anatomical structures of the respiratory system. Describe the relationship between volume and pressure. Describe changes in
More information1. IDENTIFICATION OF THE SUBSTANCE OR PREPARATION AND OF THE COMPANY. Cleaning Agent.
1. IDENTIFICATION OF THE SUBSTANCE OR PREPARATION AND OF THE COMPANY Identification of Preparation: Date of Safety Data Sheet: 26 October, 2014 Date of Re-Issue: April 27, 2015 Use of Preparation: Cleaning
More information: 634C Liquid Silicone 1 lb. Jar
SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product form Product name Product code : Mixture : 634C Liquid Silicone 1 lb. Jar : 634C 1.2. Relevant
More informationSafety Data Sheet. SECTION 1: Identification. SECTION 2: Hazard identification
Safety Data Sheet Copyright,2016,3M Company. All rights reserved. Copying and/or downloading of this information for the purpose of properly utilizing 3M products is allowed provided that: (1) the information
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationSAFETY DATA SHEET. 1. Product And Company Identification. 2. Hazards Identification
SDS ID: SDS 1200000 PRODUCT IDENTITY: Sweeping Compound DISTRIBUTOR: Uline Shipping Supplies 12575 Uline Drive Pleasant Prairie, WI 53158 1-800-295-5510 EMERGENCY PHONE NUMBER: Chemtrec (800) 424-9300
More information1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING
SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier PULMICORT SUSPENSION FOR Details of the supplier of the safety data sheet : ASTRAZENECA PTY
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Useable for: BA E-5900 BA E-8900 BA E-9900 Serotonin Research ELISA Fast Track Serotonin ELISA Serotonin ELISA Dry Blood Spot These Assays contain no hazardous substances in
More informationEcallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies
Ecallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies Albert L. Sheffer, MD, a Marilyn Campion, MS, b Robyn J. Levy, MD, c H. Henry Li, MD,
More informationDifferent Health Scenarios to Prepare Calves for Shipping and for Receiving Yearling Cattle 1
VM113 Different Health Scenarios to Prepare Calves for Shipping and for Receiving Yearling Cattle 1 E. J. Richey, DVM 2 Preparing Calves Preparing a calf to withstand the disease challenges, ration changes,
More informationPolypropylene Safety Data Sheet
SECTION 1: IDENTIFICATION OF THE SUBSTANCE 1. Intended Use of the Product Use of the Substance/Mixture: For professional use only SECTION 2: HAZARDS IDENTIFICATION 2.1. Classification of the Substance
More information: CSP R-97 Water Repellent
SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name : 1.2. Relevant identified uses of the substance or mixture and uses advised against
More informationOHRP Guidance on Written IRB Procedures
Office for Human Research Protections (OHRP) Department of Health and Human Services Date: OHRP Guidance on Written IRB Procedures Scope: This document outlines the required elements of written Institutional
More informationSECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY
Sonoma Expanded PVC Revision Date: 12/20/2013 Version: 1.0 SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY 1.1. Product Identifier Product Form: Mixture Product Name: Sonoma PVC Synonyms:
More informationClinical Skills. Administering Oxygen
Clinical Skills Administering Oxygen Updated July 2017 Clare Cann Original 2012 Carole Loveridge, Lecturer in Women`s Health Aims and Objectives Aims and Objectives The aim of this module is to facilitate
More informationNot available. S05999 (1 x 0.5mL vials), S06002 (10 x 0.5 vials) 63 Poplar Road, Parkville, Victoria 3052, Australia (24hr)
Pneumovax 23 SAFETY DATA SHEET Page 1 of 5 - IMPORTANT NOTICE This Safety Data Sheet (SDS) is prepared by Seqirus Pty. Ltd. in accordance with Safe Work Australia National Code of Practice for the Preparation
More informationChapter 5: Methods and Philosophy of Statistical Process Control
Chapter 5: Methods and Philosophy of Statistical Process Control Learning Outcomes After careful study of this chapter You should be able to: Understand chance and assignable causes of variation, Explain
More informationProduct Safety Information
First Issue February 2017 Product Safety Information Kingspan PalDuct PIR Panel 1 Identification of Products and Company 1.1 Product Identifier Product Name: Product Code: Kingspan PalDuct PIR panel. ART/P/80
More informationUNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH I. PURPOSE This document outlines the required elements of University of Tennessee
More information1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING
SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier NEOSTIGMINE SOLUTION FOR Details of the supplier of the safety data sheet : ASTRAZENECA PTY
More informationMaterial Safety Data Sheet Superwool Hardener
1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER Product Name: Other Names: SUPERWOOL HARDENER Superwool Rigidiser Recommended Use: Surface hardener for low bio-persistent synthetic mineral fibres. Manufacturer's
More informationWATKINS NITROPHOSKA PERFEKT. Yates New Zealand, a division of DuluxGroup (New Zealand) Pty Ltd ABN Co
1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER Product Name: Recommended Use: WATKINS NITROPHOSKA PERFEKT Fertiliser. Supplier: Yates New Zealand, a division of DuluxGroup (New Zealand) Pty Ltd ABN 55
More informationThe Wilson and Jungner principles of screening and genetic testing
Leeds Institute of Health Sciences The Wilson and Jungner principles of screening and genetic testing Professor Darren Shickle Academic Unit of Public Health European Forum for Evidenced-based Prevention
More information: Neutra-Hyde Neutralizer
Date of issue: 01/26/2017 Revision date: Version : 1.0 SECTION 1: Identification 1.1. Identification Product name Product code : Neutralizer : DNS-1002 1.2. Relevant identified uses of the substance or
More informationAcademic Grant CPR process monitors provided by Zoll. conflict of interest to declare
Comparison of Bystander Fatigue and CPR Quality when Using Ui Continuous Chest Compressions Versus 30:2 Compressions to Ventilations: A Randomized Cross over over Trial CAEP Niagara Falls 2012 CAEP St
More informationHI-TEMP FOOD GRADE. Food Grade Anti-Seize Compound SAFETY DATA SHEET SECTION 1: IDENTIFICATION
Manufacturer: Anti-Seize Technology 2345 N. 17th Ave. Franklin Park, IL 60131 Phone: 847-455-2300 Toll Free: 800 991-1106 Web: antiseize.com HI-TEMP FOOD GRADE Food Grade Anti-Seize Compound SAFETY DATA
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More information: Sulfate Standard, 100 ppm
Date of issue: 04/18/2013 Revision date: 04/18/2013 Supersedes: 04/07/2010 Version: 1.0 SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product
More informationANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Ruconest 2100 U powder for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 2100 units
More informationIDQ Operating, Inc. 44 Old Ridgebury Road Suite 300 Danbury, CT Tel Product And Company Identification
1. Product And Company Identification Product Name: IDQ 374 Responsible Party: Information Phone Number: +1 203-205-2900 Emergency Phone Number: For Medical Emergencies, call 1-866-949-6465 / +1 303-389-1332
More informationSafety Data Sheet Safety Data Sheet in accordance with regulation (EC) No 1907/2006, as amended. Date of issue: 31/05/2017 Version: 1.
in accordance with regulation (EC) No 1907/2006, as amended. Date of issue: 31/05/2017 Version: 1.0 SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier
More informationVisGlow plus Chemiluminescent Substrate, HRP Authorization date: 1/1/2008 Revision date: 1/1/2008 Print Date: 20/2/2008 Version: 1
Page: 1/6 Material Safety Data Sheet VisGlow plus Chemiluminescent Substrate, HRP Authorization date: 1/1/2008 Revision date: 1/1/2008 Print Date: 20/2/2008 Version: 1 1. IDENTIFICATION OF THE SUBSTANCE/
More information